AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32873678 — intervention group
Group type: COMPARATOR
Intervention: RYGB
Number of subjects: 183
Study 35837991 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily
Number of subjects: 23
Study 35837991 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride 2 mg daily
Number of subjects: 23
Study 34610611 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifunctional cocktail
Number of subjects: 90
Study 34610611 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 90
Study 34251886 — intervention group
Group type: EXPERIMENTAL
Intervention: T-Tilt position (15° Trendelenburg and 15° airplane away from the surgical side kidney)
Number of subjects: 138
Study 34251886 — intervention group
Group type: COMPARATOR
Intervention: Standard position
Number of subjects: 138
Study 34251886 — intervention group
Group type: EXPERIMENTAL
Intervention: Both positions
Number of subjects: 138
Study 33109244 — intervention group
Group type: EXPERIMENTAL
Intervention: Boron compounds (5 mg) twice a day for two weeks
Number of subjects: 40
Study 33109244 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleoylethanolamide (200 mg) twice a day for two weeks
Number of subjects: 40
Study 33109244 — intervention group
Group type: EXPERIMENTAL
Intervention: Boron compounds (5 mg) with oleoylethanolamide (200 mg) twice a day for two weeks
Number of subjects: 40
Study 33109244 — intervention group
Group type: COMPARATOR
Intervention: Routine treatments only (no additional treatment)
Number of subjects: 40
Study 34487313 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth app ReMind (10-week program including psychoeducation, strategy-training, and attention retraining)
Number of subjects: 62
Study 34487313 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 62
Study 32367694 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen at 4 L/min via nasal cannula during exercise
Number of subjects: 72
Study 32367694 — intervention group
Group type: COMPARATOR
Intervention: Placebo air at 4 L/min via nasal cannula during exercise
Number of subjects: 72
Study 34983478 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education intervention (4 sessions of 60-min education)
Number of subjects: 80
Study 34983478 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instruction)
Number of subjects: 80
Study 33992717 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily CCTRT at 65 Gy in 26 fractions
Number of subjects: 182
Study 33992717 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily CCTRT at 45 Gy in 30 fractions
Number of subjects: 182
Study 32800971 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported movement restriction scale
Number of subjects: 100
Study 32800971 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapists' interpretation of cervical ROM
Number of subjects: 100
Study 32800971 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between physical therapists (PTs)
Number of subjects: 100
Study 32800971 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective measure of cervical ROM
Number of subjects: 100
Study 34728032 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte beverage
Number of subjects: 15
Study 34728032 — intervention group
Group type: COMPARATOR
Intervention: Plain boiled water
Number of subjects: 15
Study 32638615 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Integrative Therapy (PI Therapy)
Number of subjects: 48
Study 32638615 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Integrative Therapy + Nutritional Supplements (PI Therapy + Supps)
Number of subjects: 48
Study 32638615 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 48
Study 33036734 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive radical hysterectomy
Number of subjects: 12
Study 33036734 — intervention group
Group type: COMPARATOR
Intervention: Open radical hysterectomy
Number of subjects: 12
Study 34081673 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Assessment for Public Health Emergency Response (CASPER)
Number of subjects: 178
Study 33518729 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing retraining with chest wall mobilization
Number of subjects: 32
Study 33518729 — intervention group
Group type: COMPARATOR
Intervention: Rest for 30 minutes (Control)
Number of subjects: 32
Study 34351533 — intervention group
Group type: EXPERIMENTAL
Intervention: Engager plus usual care
Number of subjects: 280
Study 34351533 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 280
Study 35776254 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP use stigma
Number of subjects: 307
Study 35776254 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of PrEP use to sexual partner and belief that PrEP prevents HIV
Number of subjects: 307
Study 35776254 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear and shame about people living with HIV
Number of subjects: 307
Study 35354324 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-Facilitating Intervention (AFI)
Number of subjects: 398
Study 35354324 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 398
Study 32375651 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum-elastic bougie (GEB)
Number of subjects: 209
Study 32375651 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube + stylet
Number of subjects: 209
Study 35947349 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg every 4 weeks (Q4W)
Number of subjects: 738
Study 35947349 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg at weeks 0 and 4 and then every 8 weeks (Q8W)
Number of subjects: 738
Study 35947349 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 738
Study 35947349 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab (after crossover from placebo at week 24)
Number of subjects: 738
Study 34059406 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group adolescents watched a video and completed an asthma question prompt list before their visits.
Number of subjects: 359
Study 34059406 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 359
Study 32723804 — intervention group
Group type: EXPERIMENTAL
Intervention: Daprodustat 4 mg once daily
Number of subjects: 271
Study 32723804 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa 10-60 μg once weekly
Number of subjects: 271
Study 35797441 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy (BIS)
Number of subjects: 918
Study 35797441 — intervention group
Group type: COMPARATOR
Intervention: Tape measurement (TM)
Number of subjects: 918
Study 34787656 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride 5 mg or 10 mg (1 or 2 tablets) 4 times daily for a maximum of 3 weeks
Number of subjects: 120
Study 34787656 — intervention group
Group type: COMPARATOR
Intervention: Combination acetaminophen and codeine 500 mg and 8 mg or 1000 mg and 16 mg (1 or 2 tablets) 4 times daily for a maximum of 3 weeks
Number of subjects: 120
Study 32726431 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive therapy (PET)
Number of subjects: 94
Study 32726431 — intervention group
Group type: EXPERIMENTAL
Intervention: Older donor age
Number of subjects: 94
Study 32726431 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset viremia (within 4 weeks)
Number of subjects: 94
Study 32682357 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 0.0625% bupivacaine plus 2 μg/mL of fentanyl
Number of subjects: 81
Study 32682357 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 0.0625% bupivacaine plus 2 μg/mL of fentanyl
Number of subjects: 81
Study 32682357 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL of 0.0625% bupivacaine plus 2 μg/mL of fentanyl
Number of subjects: 81
Study 34747048 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 81
Study 34747048 — intervention group
Group type: COMPARATOR
Intervention: Moderate Intensity Continuous Training (MICT)
Number of subjects: 81
Study 33581975 — intervention group
Group type: EXPERIMENTAL
Intervention: Static spacer
Number of subjects: 52
Study 33581975 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulating spacer
Number of subjects: 52
Study 36424662 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated renal replacement therapy (RRT) initiation
Number of subjects: 2927
Study 36424662 — intervention group
Group type: COMPARATOR
Intervention: Standard renal replacement therapy (RRT) initiation
Number of subjects: 2927
Study 36424662 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated RRT initiation
Number of subjects: 2927
Study 34535644 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg twice a day of berberine ursodeoxycholate
Number of subjects: 100
Study 34535644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 33165938 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 221
Study 33165938 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 221
Study 33165938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 34822189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-ornithine L-aspartate (LOLA) at a dose of 30 g over 24 hours for 5 days, combined with lactulose and rifaximin
Number of subjects: 140
Study 34822189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-ornithine L-aspartate (LOLA)
Number of subjects: 140
Study 34822189 — intervention group
Group type: COMPARATOR
Intervention: Placebo, lactulose, and rifaximin
Number of subjects: 140
Study 32416690 — intervention group
Group type: EXPERIMENTAL
Intervention: HGF gene therapy (naked plasmid DNA encoding hepatocyte growth factor)
Number of subjects: 77
Study 32416690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 35256225 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive analgesia (300 mg gabapentin, 200 mg celecoxib, 500 mg acetaminophen 2 hours before surgery)
Number of subjects: 44
Study 35256225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 34836092 — intervention group
Group type: COMPARATOR
Intervention: 2′FL/LNnT 10g
Number of subjects: 58
Study 34836092 — intervention group
Group type: COMPARATOR
Intervention: 2′FL/LNnT 5g
Number of subjects: 58
Study 34836092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 32058878 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance feedback on the recollection task
Number of subjects: 59
Study 32058878 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with psychosis
Number of subjects: 59
Study 32058878 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 59
Study 33787841 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with mFOLFIRINOX
Number of subjects: 0
Study 33787841 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant treatment
Number of subjects: 0
Study 33787841 — intervention group
Group type: COMPARATOR
Intervention: Precision oncology with genomic and somatic testing
Number of subjects: 0
Study 32469893 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular electroporation of HIV-MAG DNA vaccine
Number of subjects: 45
Study 32469893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 33477316 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy + exercise
Number of subjects: 48
Study 33477316 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 48
Study 32276953 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief family psychoeducation (FPE) provided by visiting nurses
Number of subjects: 47
Study 32276953 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 47
Study 36202198 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zanamivir 300 mg
Number of subjects: 488
Study 36202198 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zanamivir 600 mg
Number of subjects: 488
Study 36202198 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oseltamivir 75 mg
Number of subjects: 488
Study 36202198 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Recovery Scale on Day 6
Number of subjects: 488
Study 34783729 — intervention group
Group type: EXPERIMENTAL
Intervention: Utrecht Work Engagement Scale‐Student (UWES‐S) - exploratory factor analysis with group A
Number of subjects: 898
Study 34783729 — intervention group
Group type: EXPERIMENTAL
Intervention: Utrecht Work Engagement Scale‐Student (UWES‐S) - confirmatory factor analysis with group B
Number of subjects: 898
Study 32418809 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transspinal Direct Current Stimulation (tsDCS) at low thoracic level (20 min, 2.5 mA, cathode on shoulder)
Number of subjects: 0
Study 32418809 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 0
Study 35277038 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-modified oil oral nutritional supplement (EMO-ONS)
Number of subjects: 10
Study 35277038 — intervention group
Group type: COMPARATOR
Intervention: Standard triacylglycerol-based ONS product (TAG-ONS) with PERT
Number of subjects: 10
Study 35277038 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EMO-ONS and TAG-ONS+PERT
Number of subjects: 10
Study 32574844 — intervention group
Group type: EXPERIMENTAL
Intervention: SCF (12 g/d)
Number of subjects: 240
Study 32574844 — intervention group
Group type: EXPERIMENTAL
Intervention: SCF (12 g/d) + 600 mg/d of calcium
Number of subjects: 240
Study 32574844 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 240
Study 32574844 — intervention group
Group type: COMPARATOR
Intervention: Placebo + 600 mg/d of calcium
Number of subjects: 240
Study 36224575 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted balance treatment using the Hunova® robotic platform for 3 times a week, for 4 weeks (12 total sessions), 45 min of treatment, in addition to conventional treatment.
Number of subjects: 24
Study 36224575 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment as per daily routine.
Number of subjects: 24
Study 34836225 — intervention group
Group type: EXPERIMENTAL
Intervention: 770 mg of Tribulus terrestris L. supplementation
Number of subjects: 30
Study 34836225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 34571001 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Optical Coherence Tomography (D-OCT)
Number of subjects: 50
Study 32687266 — intervention group
Group type: EXPERIMENTAL
Intervention: Eflapegrastim (13.2 mg, 3.6 mg G-CSF)
Number of subjects: 237
Study 32687266 — intervention group
Group type: COMPARATOR
Intervention: Pegfilgrastim (6 mg G-CSF)
Number of subjects: 237
Study 32687266 — intervention group
Group type: EXPERIMENTAL
Intervention: Eflapegrastim
Number of subjects: 237
Study 32687266 — intervention group
Group type: EXPERIMENTAL
Intervention: Eflapegrastim and Pegfilgrastim
Number of subjects: 237
Study 36147622 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT)
Number of subjects: 192
Study 36147622 — intervention group
Group type: COMPARATOR
Intervention: Enhanced lower limb therapy (ELLT)
Number of subjects: 192
Study 36147622 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation therapy (CRT)
Number of subjects: 192
Study 35368494 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (daily text message for 30 days)
Number of subjects: 76
Study 35368494 — intervention group
Group type: COMPARATOR
Intervention: Control (one-time, face-to-face, brief didactic structured educational session)
Number of subjects: 76
Study 33259665 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE/TB+ patients
Number of subjects: 249
Study 33259665 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE/TB+ patients with poorer in-hospital outcomes
Number of subjects: 249
Study 33259665 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive T-SPOT.TB test and lymphocytopenia
Number of subjects: 249
Study 33259665 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocytopenia
Number of subjects: 249
Study 33772557 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate pain / moderate fatigue
Number of subjects: 193
Study 33772557 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild pain / moderate fatigue
Number of subjects: 193
Study 33772557 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate pain / mild fatigue
Number of subjects: 193
Study 33772557 — intervention group
Group type: COMPARATOR
Intervention: Mild pain / mild fatigue
Number of subjects: 193
Study 32636425 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic nano‐hydroxyapatite remineralizing gel
Number of subjects: 92
Study 32636425 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office ozone therapy
Number of subjects: 92
Study 32636425 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of domestic remineralizing gel and ozone therapy
Number of subjects: 92
Study 34460936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative open lung condition (OL)
Number of subjects: 1480
Study 34460936 — intervention group
Group type: COMPARATOR
Intervention: Non-open lung condition (NOL)
Number of subjects: 1480
Study 34344607 — intervention group
Group type: EXPERIMENTAL
Intervention: People-centred care model (PCCM) including pharmacist-led clinical medication review
Number of subjects: 277
Study 34344607 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 277
Study 34092112 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum (carboplatin or cisplatin) once every 3 weeks for four cycles
Number of subjects: 410
Study 34092112 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine 14 out of 21 days every 3 weeks for six cycles
Number of subjects: 410
Study 34092112 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum agents
Number of subjects: 410
Study 36414286 — intervention group
Group type: EXPERIMENTAL
Intervention: CareConekta smartphone application intervention
Number of subjects: 193
Study 32747351 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal education about healthy nutrition and physical activity, targeted advice for body image concerns
Number of subjects: 0
Study 32747351 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (teacher-delivered curriculum)
Number of subjects: 0
Study 34898523 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined general-epidural anesthesia (epidural group)
Number of subjects: 52
Study 34898523 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone (control group)
Number of subjects: 52
Study 32078885 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Number of subjects: 121
Study 32078885 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Training (RT)
Number of subjects: 121
Study 32078885 — intervention group
Group type: COMPARATOR
Intervention: No-Training Control (NTC)
Number of subjects: 121
Study 34437816 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm reduction e‐card (experimental group)
Number of subjects: 1064
Study 34437816 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 1064
Study 33426901 — intervention group
Group type: EXPERIMENTAL
Intervention: Research Attitudes Questionnaire scores (baseline score cutoff of 28.5)
Number of subjects: 119
Study 33426901 — intervention group
Group type: EXPERIMENTAL
Intervention: Research Attitudes Questionnaire scores (baseline score cutoff of 27.5)
Number of subjects: 119
Study 33426901 — intervention group
Group type: EXPERIMENTAL
Intervention: Research Attitudes Questionnaire scores
Number of subjects: 119
Study 33043350 — intervention group
Group type: EXPERIMENTAL
Intervention: Er: YAG laser irradiation in periodontal pocket after subgingival scaling with ultrasound and hand instruments
Number of subjects: 30
Study 33043350 — intervention group
Group type: COMPARATOR
Intervention: Subgingival scaling with ultrasound and hand instruments alone (Control)
Number of subjects: 30
Study 36415651 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedic-administered breathlessness management intervention plus usual care
Number of subjects: 13
Study 36415651 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 13
Study 32786188 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression therapy plus education on cellulitis prevention
Number of subjects: 84
Study 32786188 — intervention group
Group type: COMPARATOR
Intervention: Education alone (control group)
Number of subjects: 84
Study 36283713 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position (group P)
Number of subjects: 64
Study 36283713 — intervention group
Group type: COMPARATOR
Intervention: Sitting position (group S)
Number of subjects: 64
Study 33317326 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (gender)
Number of subjects: 4875
Study 33317326 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (gender) with DNR order
Number of subjects: 4875
Study 33317326 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (gender) without WLST
Number of subjects: 4875
Study 33317326 — intervention group
Group type: COMPARATOR
Intervention: Women (gender) with WLST
Number of subjects: 4875
Study 32284390 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs that explicitly described who was blinded in a trial
Number of subjects: 622
Study 32284390 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs that reported any information about blinding
Number of subjects: 622
Study 32284390 — intervention group
Group type: EXPERIMENTAL
Intervention: Manuscripts fully reporting the status of blinding
Number of subjects: 622
Study 32284390 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrepancies in blinding information
Number of subjects: 622
Study 32284390 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey of authors' definitions of blinding
Number of subjects: 622
Study 36062713 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissociative Identity Disorder (DID)
Number of subjects: 139
Study 36062713 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia
Number of subjects: 139
Study 36062713 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive Disorders
Number of subjects: 139